BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) UNBUZZD Definitive Agreement Featured by Investment Pitch Media

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, is spotlighted on the latest InvestmentPitch Media release. The media release discusses FSD Pharma’s recently executed definitive agreement that grants exclusive rights to Celly Nutrition for recreational applications of its alcohol misuse technology and the launch of UNBUZZD(TM), a revolutionary rapid alcohol detoxification drink. According to the agreement, Celly Nu will pay FSD a license fee by issuing 100,000,000 shares and a 7% royalty on gross revenue if a product is commercialized while FSD will retain all rights to medical and pharmaceutical applications under its umbrella to further develop the franchise. A new great-tasting functional beverage, UNBUZZD has been by FSD Pharma to provide relief from inebriation and accelerating alcohol metabolism.

The beverage contains a proprietary formulation of natural ingredients, vitamins and minerals and assists with liver and brain function to reduce the effects of alcohol consumption. The formulation was curated through scientific research to expediate recovery from inebriation and to accelerate ethanol metabolism in your body, potentially eliminating any performance concerns, the announcement noted. “Zeeshan Saeed, President and Executive Co-Chairman, stated: “This is a major milestone for our company,” said FSD Pharma president and executive cochair Zeeshan Saeed in the press release. “It is a huge step in taking our science to a commercialized product. We have the best and brightest people leading this product commercialization and roll-out, as they were instrumental in the breakthrough, significant ramp up and success with Celsius.”

To view the full media release, visit https://ibn.fm/IGUBN

To view the full press release, visit https://ibn.fm/P4Wtt

About FSD Pharma Inc.

FSD Pharma Inc. is a biotechnology company with two candidates in different stages of development. Lucid Psychss Inc., a wholly owned subsidiary, is focused on the research and development of its lead compounds, Lucid-MS and UNBUZZD(TM). Lucid-MS is a molecular compound identified for the potential treatment of neurodegenerative disorders. UNBUZZD is a proprietary formulation of natural ingredients, vitamins and minerals to help with liver and brain function for the purposes of potentially quickly relieving from the effects of alcohol consumption, such as inebriation, and restoring normal lifestyle. For more information about the company, please visit www.FSDPharma.com.

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork